FCR

SuperMeat's Forward-Facing LCA Highlights 50% Decrease in Carbon Footprint of Chicken, the Most Efficient Animal Protein

Retrieved on: 
Wednesday, March 20, 2024
Carbon, Meat, Particulates, Research, SuperMeat, FCR, Carbon footprint, LCA, Agriculture

The assessment provides a detailed comparative analysis between SuperMeat's 100% cultivated chicken and the most sustainably produced traditional chicken aspired for the outset of the 2030s.

Key Points: 
  • The assessment provides a detailed comparative analysis between SuperMeat's 100% cultivated chicken and the most sustainably produced traditional chicken aspired for the outset of the 2030s.
  • SuperMeat's cultivated chicken is projected to achieve a carbon footprint approximately 50% lower than the ambitious benchmarks set for conventional chicken production, when integrating renewable energy sources and sustainable production practices in both conventional and cultivated production methods.
  • Even under the reliance on standard grid electricity, a 27% reduction in the carbon footprint of SuperMeat's chicken is achieved, in comparison to the ambitious conventional chicken benchmark.
  • A Highly Efficient Production Process Fuels SuperMeat's Sustainability Milestones:
    SuperMeat's continuous production process will be instrumental in achieving the expected sustainability outcomes for its cultivated chicken.

Operata Has Been Awarded Selection for the Innovation Showcase at Enterprise Connect 2024 (EC24) for Advancing Customer Experience With CX Observability

Retrieved on: 
Tuesday, March 26, 2024
Software, Data Analytics, Marketing, Artificial Intelligence, Communications, Professional Services, Technology, Electronic Commerce, Cloud, Organization, Communication, Health, TTR, CX, Enterprise, Insurance, AHT, FCR, Multimedia, CPU, Sales

Operata has been awarded selection for the Innovation Showcase at Enterprise Connect 2024 (EC24), marking a significant achievement in its commitment to enhancing the efficiency and functionality of contact centers through CX Observability.

Key Points: 
  • Operata has been awarded selection for the Innovation Showcase at Enterprise Connect 2024 (EC24), marking a significant achievement in its commitment to enhancing the efficiency and functionality of contact centers through CX Observability.
  • The selection of Operata for the Innovation Showcase at Enterprise Connect 2024 (EC24) recognizes it among cutting-edge technologies enhancing customer experiences.
  • The recognition of Operata at EC24 for its innovation in CX Observability underscores the company's unique approach.
  • In light of its selection for the Innovation Showcase, Operata is offering EC attendees a chance to experience the advantages of CX Observability with a free trial.

Bixia Expands Trading Operations With Hansen

Retrieved on: 
Thursday, March 21, 2024
Other Energy, Software, Utilities, Networks, Oil, Gas, Alternative Energy, Energy, Technology, Chinese gods and immortals, HSN, ECP, Automation, Software as a service, Partnership, Part, ASX, Blog, FCR, Water, 3D printing

Under this agreement, Bixia will expand its trading capabilities by leveraging Hansen Trade’s modularity to add the FCR (Frequency Containment Reserve) and mFRR (Manual Frequency Restoration Reserve) Ancillary Services trading and automatic customer communication components.

Key Points: 
  • Under this agreement, Bixia will expand its trading capabilities by leveraging Hansen Trade’s modularity to add the FCR (Frequency Containment Reserve) and mFRR (Manual Frequency Restoration Reserve) Ancillary Services trading and automatic customer communication components.
  • This expansion builds upon Bixia’s current deployment of Hansen Trade for intraday trading , initiated earlier last year.
  • The Hansen Trade FCR module enables Bixia to operate automatically in the FCR market, including automatic bid sending and trade-result handling.
  • Introducing Hansen’s FCR and mFRR trading modules will significantly upgrade our trading-related service and provide our customers with a modern trading service experience.

Hamline University Research Validates Highly Cost-Effective Impairment Assessment Algorithm for Workers' Compensation Cases

Retrieved on: 
Wednesday, April 3, 2024
Physics, NP-hardness, Health, American Medical Association, Headache, Patient, FLR, Research, Table, Doctor of Philosophy, MD, Insurance, ADL, Lawyer, FCR, Heart, WPI, QME, Fifth Edition, Hamline University, Nursing

ST. PAUL, Minn., April 3, 2024 /PRNewswire-PRWeb/ -- Hamline University, in collaboration with impairment rating calculations company Rate-Fast, today announced groundbreaking research that revolutionizes the assessment of impairment in workers' compensation cases. The study validates a novel algorithm-based Functional Loss Rating (FLR) method, which offers a more objective, efficient, and cost-effective approach for calculating a whole-person impairment (WPI) score, upon which compensation for work-related injuries is based. The study demonstrates that the computational FLR method is consistently more accurate than the traditional, manual Four Corners Rating (FCR) system, the current industry standard for WPI measurement.

Key Points: 
  • ST. PAUL, Minn., April 3, 2024 /PRNewswire-PRWeb/ -- Hamline University, in collaboration with impairment rating calculations company Rate-Fast, today announced groundbreaking research that revolutionizes the assessment of impairment in workers' compensation cases.
  • The study validates a novel algorithm-based Functional Loss Rating (FLR) method, which offers a more objective, efficient, and cost-effective approach for calculating a whole-person impairment (WPI) score, upon which compensation for work-related injuries is based.
  • FLR is a mathematical impairment evaluation method that uses advanced data analytics to calculate an objective, accurate WPI rating.
  • The algorithm at the heart of FLR was built on more than a decade of research comprised of nearly 70,000 impairment case rating experiences.

ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

Retrieved on: 
Wednesday, February 7, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Parasitism, Coccidiosis, Agriculture, Immune system, OTCQB, Bird, Parity, Poultry, Disease, FCR, Feed conversion ratio, Poultry farming

Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.

Key Points: 
  • Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.
  • These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain.
  • ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry.
  • We believe these findings will facilitate and expand dialogues with potential partners in the agriculture and animal health industries,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience.

EPV Expands Utilisation of Hansen’s Trading Solution

Retrieved on: 
Wednesday, January 24, 2024
Software, Networks, Other Energy, Professional Services, Utilities, Data Management, Alternative Energy, Energy, Technology, Other Communications, Data Analytics, Communications, HSN, ASX, FCR, Data management, FFR, Part, Power, Partnership, Software as a service, Water, EPV, Renewable energy

As part of the agreement, EPV will leverage the modular capabilities of Hansen Trade by expanding its utilisation of the trading solution to encompass aFRR and FCR market trading.

Key Points: 
  • As part of the agreement, EPV will leverage the modular capabilities of Hansen Trade by expanding its utilisation of the trading solution to encompass aFRR and FCR market trading.
  • This expansion builds upon EPV’s current deployment of Hansen Trade Intraday Trading, Day-Ahead Trading and Regulating Power Market (mFRR) operations.
  • With Hansen Trade, EPV will be able to operate in all physical trading marketplaces, including Nord Pool’s Intraday and Day-Ahead markets, as well as the mFRR, aFRR, FCR and FFR markets.
  • Mika Luoto, Head of Operations at EPV, commented: “Over the years, Hansen’s unwavering commitment to product development has consistently surpassed our expectations.

Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches

Retrieved on: 
Sunday, December 10, 2023
Human, Woman, ASH, Patient, Research, Infection, Navitoclax, Venetoclax, Cancer, Doctor of Philosophy, Anemia, Mutation, Bone marrow, Food, Progression-free survival, Acute myeloid leukemia, Leukemia, Male, AbbVie, Blood, Diarrhea, Bleeding, Family, Ruxolitinib, Society, San Diego Convention Center, Primary myelofibrosis, Spleen, SAN, Data, PFS, MD Anderson Cancer Center, University, Splenomegaly, Phase, Pain, Cell, B cell, JAK, FCR, Disease, Abdomen, Fatigue, MRD, Weakness, Chronic lymphocytic leukemia, Standard of care, MB, CLL, Lymphoma, Pharmaceutical industry, Medical imaging, Dentistry, Vaccine, Medical device, MD

SAN DIEGO, Dec. 10, 2023 /PRNewswire/ -- Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, and how a powerful, relatively new prognostic tool is helping identify patients who are more or less likely to benefit from both older and newer treatments.

Key Points: 
  • Two other studies presented in this session spotlight ways in which a novel prognostic tool is demonstrating its value across a range of blood cancers.
  • The researchers used MRD to determine how long patients in the targeted-agents group should continue treatment.
  • These cells develop into specialized blood cells, such as red and white blood cells and platelets, that also carry the mutation.
  • By comparison, progression-free survival (PFS) for patients receiving the standard of care was 76.8% with a death rate of 7%.

BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Pharmaceutical, Health, Oncology, National Institute for Health and Care Excellence, SSE, United Kingdom, BGNE, BR, Leeds Teaching Hospitals NHS Trust, TP53, NICE, FCR, NHS, Disease, Leukemia, Healthcare Improvement Scotland, FDG, BTK, Patient, SEQUOIA, Pharmaceutical industry, CLL, EU, BeiGene

“This follows the previous approval of BRUKINSA by NICE in July 2022 as the only cost-effective treatment for patients with Waldenstrom’s macroglobulinemia.

Key Points: 
  • “This follows the previous approval of BRUKINSA by NICE in July 2022 as the only cost-effective treatment for patients with Waldenstrom’s macroglobulinemia.
  • “This decision represents a significant milestone for patients in England and Wales with CLL, the most common form of leukemia in adults,” said Nick York, Patient Advocacy Healthcare Liaison Officer, U.K. Leukemia Care.
  • “Despite continued treatment advances, many patients with CLL will relapse and need additional treatment options.
  • Furthermore, a proportion of patients have a disease which is refractory to initial treatment.”
    BRUKINSA is the third BTKi for CLL to be recommended by NICE for routine commissioning.

FAN CONTROLLED SPORTS FEEDS FANS NEED FOR SPEED WITH SS GREENLIGHT RACING TEAM PARTNERSHIP; EXPANSION INTO MOTORSPORTS LAUNCHING AT NASCAR XFINITY SERIES CHAMPIONSHIP RACE

Retrieved on: 
Tuesday, October 17, 2023
Experience Points, Mustang, Partnership, Ford, Paint, Android, NBCSN, USA Network, FCF, Networking hardware, IOS, NASCAR Xfinity Series, NASCAR, Fan Controlled Football, FCR, 2020 NASCAR Xfinity Series, NASCAR Drivers: Non-Stop, VIP, Crew, Sport

LOS ANGELES, Oct. 17, 2023 /PRNewswire/ -- Fan Controlled Sports & Entertainment (FCSE), the creators of Fan Controlled Football (FCF), today introduces Fan Controlled Racing (FCR), giving the next generation of motorsports fans unparalleled live interactivity and control of a racecar. In partnership with SS Greenlight Racing and The Magnifyde Agency, FCR will take control of the #08 Ford Mustang, empowering fans to make critical decisions from selecting the driver and the paint scheme to determining live race strategies, including when to pit and which lane to pick after restart.

Key Points: 
  • "We couldn't be more excited about bringing the energy and interactivity of Fan Controlled Sports to the racetrack," said FCSE co-founder Patrick Dees.
  • In the build-up to the race, fans will design the Fan Controlled #08's paint scheme and help set the strategy for their team.
  • The driver chosen by the fans will take the wheel for the Fan Controlled #08 car in the NASCAR Xfinity Series Championship Race on November 4th.
  • FCR aims to expand with motorsports partnerships worldwide to create interactive live experiences for the next generation of racing fans.

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

Retrieved on: 
Monday, October 9, 2023
CSU, Basophil, Antibody, Biology, Inflammation, Apoptosis, Risk, Rockefeller, KOL, Stanford University School of Medicine, Survival, FCR, Microbiology, B cell, Transplant, Patient, Stem cell factor, Infection, Therapy, Stanford Institutes of Medicine Summer Research Program, CD117, Fraunhofer Society, Berlin, Immunology, Immunity, S-1 Executive Committee, Hives, Syndrome, Pharmacology, SCF, Rockefeller University, FC, Executive Committee, Translational medicine, Vaccine, Pathology, Dermatology, Allergy, Jasper

Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.

Key Points: 
  • Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients.
  • Briquilimab is an unconjugated aglycosylated anti-c-Kit antibody that blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF).
  • This mechanism of action disrupts the critical survival signal, leading to mast cell apoptosis thereby removing the underlying source of the inflammatory response in chronic urticaria.
  • He is also a member of the Executive Committee of the Stanford Institute for Immunity, Transplantation and Infection.